Current Diabetes Reports

, Volume 8, Issue 1, pp 31–36

Challenges in developing drugs for the metabolic syndrome

Article
  • 41 Downloads

Abstract

Metabolic syndrome refers to a clustering of established and emerging cardiovascular disease (CVD) risk factors within a single individual. The established risk factors—such as obesity, diabetes, dyslipidemia, hypertension—and other emerging risk factors are closely related to central obesity (especially intra-abdominal adiposity). Insulin resistance is also an important factor in this syndrome’s etiology. However, despite the potential use of having all the CVD risk factors under an umbrella diagnosis of metabolic syndrome, debate continues about the very existence of the metabolic syndrome. Despite the controversies, many existing therapies and new drugs in development are targeting the metabolic syndrome. To date, no drugs are approved specifically for treating the metabolic syndrome. This article discusses some of the challenges in developing therapies for the metabolic syndrome.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Grundy SM: Controversies in clinical endocrinology. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007, 92:399–404.PubMedCrossRefGoogle Scholar
  2. 2.
    Fonseca V: Risk factors for coronary heart disease in diabetes. Ann Intern Med 2000, 133:154–156.PubMedGoogle Scholar
  3. 3.
    Lawlor DA, Lean M, Sattar N: ABC of obesity: obesity and vascular disease. BMJ 2006, 333:1060–1063.PubMedCrossRefGoogle Scholar
  4. 4.
    Reaven GM: Role of insulin resistance in humans. Diabetes 1988, 37:1595–1607.PubMedCrossRefGoogle Scholar
  5. 5.
    Kahn R, Buse J, Ferrannini E, et al.: The metabolic syndrome: time for a critical appraisal. Diabetes Care 2005, 28:2289–2304.PubMedCrossRefGoogle Scholar
  6. 6.
    Alberti KG, Zimmet P: The metabolic syndrome: time to reflect. Curr Diab Rep 2006, 6:259–261.PubMedCrossRefGoogle Scholar
  7. 7.
    Pratley RE: Metabolic syndrome: why the controversy? Curr Diab Rep 2007, 7:56–59.PubMedCrossRefGoogle Scholar
  8. 8.
    Ferrannini E: Controversies in clinical endocrinology. Metabolic syndrome: a solution in search of a problem. J Clin Endocrinol Metab 2007, 92:396–398.PubMedCrossRefGoogle Scholar
  9. 9.
    Hossain P, Kawar B, El Nahas M: Obesity and diabetes in the developing world—a growing challenge. N Engl J Med 2007, 356:213–215.PubMedCrossRefGoogle Scholar
  10. 10.
    Flordellis CS, Ilias I, Papavassiliou AG: New therapeutic options for the metabolic syndrome. Trends Endocrinol Metab 2005, 16:254–260.PubMedCrossRefGoogle Scholar
  11. 11.
    Food and Drug Administration: Guidance for Industry Developing Products for Weight Management. Available at http://www.fda.gov/cder/guidance/7544dft.pdf. Accessed October 26, 2007.
  12. 12.
    Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735–2752.PubMedCrossRefGoogle Scholar
  13. 13.
    Alberti KG, Zimmet P, Shaw J: The metabolic syndrome—a new worldwide definition. Lancet 2005, 366:1059–1060.PubMedCrossRefGoogle Scholar
  14. 14.
    Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548–2556.PubMedCrossRefGoogle Scholar
  15. 15.
    Sonnenberg G, Matfin G, Reinhardt R: Drug treatments for obesity: where are we heading and how do we get there? Br J Diabetes Vasc Dis 2007, 7:111–118.CrossRefGoogle Scholar
  16. 16.
    Goldstein BJ, Scalia R: Adiponectin: a novel adipokine linking adipocyte and vascular function. J Clin Endocrinol Metab 2004, 89:2563–2568.PubMedCrossRefGoogle Scholar
  17. 17.
    Hug C, Lodish HF: Visfatin: a new adipokine. Science 2005, 307:366–367.PubMedCrossRefGoogle Scholar
  18. 18.
    Ford ES: Prevalence of the metabolic syndrome by the International Diabetes Federation among adults in the US. Diabetes Care 2005, 28:2745–2749.PubMedCrossRefGoogle Scholar
  19. 19.
    Qiao Q; DECODE Study Group: Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia 2006, 49:2837–2846.PubMedCrossRefGoogle Scholar
  20. 20.
    Gami AS, Witt BJ, Howard DE, et al.: Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007, 49:403–414.PubMedCrossRefGoogle Scholar
  21. 21.
    Tushuizen ME, Diamant M, Heine RJ: Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes. Postgrad Med 2005, 81:1–6.CrossRefGoogle Scholar
  22. 22.
    Pratley R, Matfin G: Pre-diabetes: clinical relevance and therapeutic approach. Br J Diabetes Vasc Dis 2007, 7:120–126.Google Scholar
  23. 23.
    Ryden L, Standl E, Bartnik M, et al.: Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007, 28:88–136.PubMedCrossRefGoogle Scholar
  24. 24.
    Buse JB, Ginsberg HN, Bakris GL, et al.: Primary prevention of cardiovascular disease in people with diabetes mellitus. A scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007, 115:114–126.PubMedCrossRefGoogle Scholar
  25. 25.
    Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363–369.PubMedCrossRefGoogle Scholar
  26. 26.
    Lee Y, Pratley R: The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep 2005, 5:70–75.PubMedCrossRefGoogle Scholar
  27. 27.
    Matfin G: Biomarkers in clinical trials and drug development: measurement of cardiometabolic risk. Br J Diabetes Vasc Dis 2007, 7:101–106.Google Scholar
  28. 28.
    Matfin G: Challenges in developing therapies for the metabolic syndrome. Br J Diabetes Vasc Dis 2007, 7:152–156.Google Scholar
  29. 29.
    Van Gaal LF, Rissanen AM, Scheen AJ, et al.: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389–1397.PubMedCrossRefGoogle Scholar
  30. 30.
    Grundy SM: Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Disc 2006, 5:295–309.CrossRefGoogle Scholar
  31. 31.
    Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003, 326:1419.PubMedCrossRefGoogle Scholar
  32. 32.
    Reddy KS: The prevention polypill—much promise, insufficient evidence. N Eng J Med 2007, 356:212.CrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Global Medical and Scientific AffairsTakeda America HoldingsDeerfieldUSA

Personalised recommendations